These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20922343)

  • 21. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
    O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
    J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
    Broulikova HM; Sladek V; Arltova M; Cerny J
    J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
    Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
    Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the societal impact of acetylcholinesterase inhibitor therapies.
    Winblad B; Wimo A
    Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
    Purandare N; Swarbrick C; Fischer A; Burns A
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):961-4. PubMed ID: 16927408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
    Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
    Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
    Jönsson L
    Pharmacoeconomics; 2003; 21(14):1025-37. PubMed ID: 13129415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
    Zala D; Chan D; McCrone P
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
    Ballard C; Sorensen S; Sharp S
    J Alzheimers Dis; 2007 Aug; 12(1):53-9. PubMed ID: 17851194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
    McDonnell J; Redekop WK; van der Roer N; Goes E; Ruitenberg A; Busschbach JJ; Breteler MM; Rutten FF
    Pharmacoeconomics; 2001; 19(4):379-90. PubMed ID: 11383754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
    Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 38. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?
    Schneider LS
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):9-13. PubMed ID: 16353164
    [No Abstract]   [Full Text] [Related]  

  • 39. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.